Key Points
- United Therapeutics CEO Martine Rothblatt sold 9,500 shares on March 11 at an average price of $539.54 for a total of $5,125,630, leaving her with 130 shares — a 98.65% reduction in her holding, disclosed in an SEC filing.
- The company reported a strong quarter with $7.70 EPS (beats $6.78) and 7.4% year-over-year revenue growth, and the stock (market cap ~$23.9B) has drawn analyst upgrades — nine Buys and three Holds with a consensus "Moderate Buy" and an average price target of $539 (several firms raised targets, e.g., UBS to $705, RBC to $643).
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $539.54, for a total transaction of $5,125,630.00. Following the completion of the sale, the chief executive officer owned 130 shares of the company's stock, valued at $70,140.20. This trade represents a 98.65% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
United Therapeutics Stock Up 1.7%
NASDAQ UTHR opened at $544.71 on Thursday. The firm has a 50-day moving average price of $484.97 and a two-hundred day moving average price of $458.01. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $548.12. The company has a market capitalization of $23.87 billion, a P/E ratio of 19.52, a P/E/G ratio of 1.93 and a beta of 0.84.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, topping the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to analysts' expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business's revenue for the quarter was up 7.4% on a year-over-year basis. During the same period last year, the firm earned $6.19 earnings per share. Equities analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.
Analyst Ratings Changes
Several equities analysts have recently commented on UTHR shares. Royal Bank Of Canada boosted their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the company an "outperform" rating in a research report on Thursday, February 26th. TD Cowen lifted their price objective on shares of United Therapeutics from $525.00 to $575.00 and gave the company a "buy" rating in a research note on Wednesday, February 25th. Jefferies Financial Group restated a "buy" rating on shares of United Therapeutics in a research report on Monday, March 2nd. UBS Group raised their target price on United Therapeutics from $655.00 to $705.00 and gave the company a "buy" rating in a report on Thursday, March 5th. Finally, Oppenheimer lifted their price target on United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, February 26th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $539.00.
Read Our Latest Research Report on UTHR
Institutional Trading of United Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the stock. Clearstead Advisors LLC grew its position in shares of United Therapeutics by 8.9% during the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company's stock valued at $117,000 after purchasing an additional 23 shares in the last quarter. Independent Advisor Alliance raised its position in shares of United Therapeutics by 3.3% in the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company's stock worth $406,000 after buying an additional 27 shares in the last quarter. Bessemer Group Inc. boosted its stake in United Therapeutics by 2.6% during the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company's stock valued at $472,000 after buying an additional 28 shares during the period. Florida Financial Advisors LLC boosted its stake in United Therapeutics by 5.4% during the fourth quarter. Florida Financial Advisors LLC now owns 550 shares of the biotechnology company's stock valued at $268,000 after buying an additional 28 shares during the period. Finally, NDVR Inc. grew its position in United Therapeutics by 5.1% during the fourth quarter. NDVR Inc. now owns 616 shares of the biotechnology company's stock worth $300,000 after buying an additional 30 shares in the last quarter. Institutional investors own 94.08% of the company's stock.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
